References
Gavaza P, Rascati KL, Oladapo AO, Khoza S. The state of health economic research in South Africa: a systematic review. Pharmacoeconomics. 2012;30(10):925–40.
Gow J, Strauss M, Whiteside A. The state of health economic research in South Africa [letter]. Pharmacoeconomics. 2013. doi:10.1007/s40273-013-0024-y.
Venkataramani AS, Maughan-Brown B, Nattrass N, Ruger JP. Social grants, welfare and the incentive to trade-off health for income among individuals on HAART in South Africa. AIDS Behav. 2010;14(6):1393–400.
Nattrass N, Geffen N. The impact of reduced drug prices on the cost-effectiveness of HAART in South Africa. Afr J AIDS Res. 2005;4(1):65–7.
Nattrass N. South Africa’s ‘rollout’ of highly active antiretroviral therapy: a critical assessment. J Acq Immune Def Synd. 2006;43(5):618–23.
Nattrass N. Modelling the relationship between antiretroviral treatment and HIV prevention: limitations of the Spectrum AIDS Impact Model in a changing policy environment. Afr J AIDS Res. 2007;6(2):129–37.
Acknowledgments
The authors have no conflicts of interest relevant to the content of this letter.
Author information
Authors and Affiliations
Corresponding author
Additional information
This reply refers to the comment available at doi:10.1007/s40273-013-0024-y.
Rights and permissions
About this article
Cite this article
Gavaza, P., Rascati, K.L., Oladapo, A.O. et al. The Authors’ Reply to Gow et al.: “The State of Health Economic Research in South Africa”. PharmacoEconomics 31, 255–256 (2013). https://doi.org/10.1007/s40273-013-0027-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40273-013-0027-8